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Abstract
Background: Breast conserving therapy (BCT) is an accepted treatment for early-stage breast cancer. This study
aimed to measure prospectively acute radiation-related toxicity and to create a comprehensive data base for long-
term temporal analyses of 3D conformal adjuvant radiotherapy. The specific aspect of age has been neglected by
traditional research. Therefore, the impact of age on acute BCT toxicity should be also specifically adressed.
Methods: Toxicity was measured in 109 patients at initiation (t1), during radiotherapy (t2-t7), and 6 weeks after
treatment completion (t8) using a new topographic module. Organ systems were recorded in 15 scales and scored
according to symptom intensity (grade 0-5) based on CTC (Common Toxicity Criteria) -classification. Radiotherapy
was virtually CT-based planned and applied with 6-MeV-photons. Mean total dose was 60.1 Gy. Patients were
stratified by age in 3 Groups: <50, 50-60, and >60 years.
Results: Registered toxicity was generally low. Mean overall-grade climbed from 0.29-0.40 (t1-t7), and dropped to
0.23 (t8). Univariate analyses revealed slightly higher toxicity in older (> 60 years) versus young patients (<50 years)
in 2 scales only: breast-symmetry (p = 0.033), and arm function (p = 0.007). However, in the scale “appetite” toxicity
was higher in younger (< 50 years) versus older (> 60 years) patients (p = 0.039). Toxicity differences in all other
scales were not significant. Between older (> 60 years) and midaged patients (50-60 years) no significant
differences in toxicity were found. This was also true for the comparison between young (<50 years) versus
midaged patient groups (50-60 years).
Conclusion: The treatment concept of BCT for breast cancer is generally well tolerated. The toxicity-measurement
with the new topographic module is feasible. Not modified standard treatment for BC should be performed in
elderly women.
Introduction
With the aging of the population, more older women
are being diagnosed with breast cancer. Over 40% of all
newly diagnosed breast cancer cases in the United States
occur in the age subgroup of postmenopausal women
and only 5% to 7% of breast carcinomas are diagnosed
in women who are younger than 40 years of age [1].
Higher mortality in younger breast cancer population
was attributed in previous studies to poorer outcomes in
early-stage disease [2-4]. Although elderly women do at
least as well as younger patients in survival time for
localized and regional stages of breast cancer, therapy-
related adverse effects and initially impaired general
health condition can influence the older individual’s
functional health status in cancer survivors. A view on
this interplay and clinical dilemma might be reflected in
the tendency of undertreatment and/or non-standard
therapy in older breast cancer population. However,
S w e e n e ye ta l .[ 5 ]p r o v i d e dd a t ao fw e l lf u n c t i o n i n g
2218 female long-term cancer survivors, when compared
with 23501 women without a cancer history (patients
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were less than 2-year cancer survivors had a higher pre-
valence of limitations than women who were survivors
of 2 or more years. Thus, recovery from effects of the
disease and its treatment would take place over time.
This is consistent with other reports [6]. These results
emphasize the need to focus on elderly women for
screening, early detection, diagnostic evaluation, and
therapy but in a more comprehensive way by analyzing
prospectively temporal variations of outcomes in com-
parison with a pre-therapeutic first assessment. This is
especially true for acute toxicity which is generally
neglected by traditional research. Therefore, knowledge
on frequency and severity of acute breast cancer ther-
apy-related morbidity is very limited.
Breast-conserving therapy (BCT) is the accepted stan-
dard treatment for early-stage breast cancer (BC) and
consists of conserving surgery (CS) and postoperative
adjuvant radiotherapy (RT) [7,8]. The current study
aimed to measure prospectively the acute treatment
toxicity in general and to create a comprehensive data
base for lomg-term temporal analyses of 3D conformal
adjuvant radiotherapy, which was developed throughout
the late 1990 s in order to lower radiotherapy-related
effects of BCT. The special aspects of age and its impact
on acute BCT-related toxicity should be also specifically
addressed.
Patients and methods
Study design and instruments
Therapy-related toxicity is an independent and important
endpoint of modern treatment concepts [9]. According
to the Radiation Therapy Oncology Group (RTOG) clas-
sification, treatment-related normal tissue reactions
between day 0 and 90 following radiotherapy initiation
are labeled “acute”. The National Cancer Institute (NCI)
developed the original Common Toxicity Criteria (CTC)
in 1982 in an effort to provide standard language for
reporting adverse events occurring in cancer clinical
trials. In the current study, the CTC criteria [10] consti-
tuted the basis of the therapy-related morbidity docu-
mentation. The acute adverse events were scored in six
categories from grade 0 (no events), grade 1 (mild event),
grade 2 (moderate event), grade 3 (severe event), grade 4
(life-threatening event), to grade 5 (death related to
adverse event). All patients consecutively treated in the
study time were selected for enrolment in order to avoid
bias by defining exclusion criteria (e.g. incomplete treat-
ment). Main aim of the study was to create a pre-irradia-
tion data base for prospective outcome analyses in order
to evaluate temporal outcome trends of the introduced
3D conformal adjuvant radiotherapy within the BCT. In
phase 1 (the present study report), the acute radiation-
r e l a t e dt o x i c i t ya n dt h es p e c i f i ca s p e c t so fa g es h o u db e
first adressed in a patient sample of n = 100. Phase 2
(subject of later report) should adress the treated patients
at long-term follow-up in comparisson with the registred
pre-therapeutic and acute morbidity. This study was an
i m p o r t a n tp a r to fab r o a da nd comprehensive depart-
ment effort to create a multi-entity electronic research
data base [11]. To this end, documentation instruments
based on the CTC classification were developed for sev-
eral anatomic- topographic body regions: central nervous
system, head & neck, breast, thorax, abdomen/pelvis [12].
These topographic modules aimed to assess with standar-
dized and organ system-related operability acute radia-
tion-caused adverse events facilitating interdisciplinary
comparisons. Total radiation treatment time for breast
cancer lasts 6 weeks. A follow-up visit 6 weeks after com-
pletion of radiotherapy is necessary to complete the acute
phase - the first three months following treatment initia-
tion. Therefore, the study design envisaged the prospec-
tive toxicity measurement at initiation (t1), during
treatment (t2-t7), and 6 weeks after radiotherapy comple-
tion (t8) using the new developed topographic module.
When age factors are presented in clinical studies for
breast cancer, they are usually reported according to the
age break of < 50 and 50 years or more to approximate
those differences imposed by menopause [13]. This cut-
off level was also used in the present study to define
young age, 50 to 60 years for midage [14], as well as >60
years for older population.
Computed tomography (CT)-based virtual radiotherapy
planning, target volumes and applied dose
The technology chain for CT-based virtual simulation
consisted in a CT-scanner, a virtual simulator, a network-
ing system, and a 3D radiotherapy planning system.
Modern linear accelerators were used for radiation appli-
cation. Interconnectivity between the various equipment
used was provided by the standard data format - Digital
Imaging and Communications in Medicine-Radiotherapy
(DICOM RT) [15]. In the planning process a CT-study
was first performed. Patients were immobilized using
standardized devices. Breast anatomy was assessed by
palpation and marked with radioopaque wires on skin,
which was important to discriminate in CT images
between breast and fatty tissue (figure 1). The first refer-
ence point was positioned in the scanned area using a
laser system and highlighted with radioopaque markers.
The CT study was then performed with a slice collima-
tion of 5 mm and exported to the virtual simulator,
where the target contouring occurred. According ICRU
(International Commission of Radiation Units and Mea-
surements) Report 50 [16] the Gross Tumor Volume
(GTV) was defined in the region of the tumor bed after
breast-conserving surgery and was expanded to the entire
breast to account for subclinical disease (Clinical Target
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tralateral breast. In nodal negative breast cancer patients
the axillar region was defined as organ at risk as well. In
addition, in left-sided tumor lesions the heart was also
taken into consideration and in right-sided tumor sites
the liver. Target contouring was performed digitally in all
transversal CT-slices. Figu r e2s h o w st h eG T Va n dt h e
CTV in one CT cross-section. The scar was also radioo-
paque marked. In the third planning step, the CT study
with digitized target volumes was exported to the radio-
therapy planning system. In Observer-Eye-View (OEV)
beam incidence, geometry and size were determined.
Each beam was then conformed in Beam-Eye-View
(BEV) perspective to the defined target using a remote
multi-leave-collimator (MLC) of a linear accelerator.
A small safety margin was added to form the Planning
Target Volume (PTV). A dose distribution as homoge-
neous as possible was than calculated. Nodal negative
patients were treated by a tangential two-field-technique
to a dose of 50 Gy. In nodal positive patients the supra-
clavicular region was additionally irradiated to a dose of
46 Gy using an asymmetric three-field-technique. In
cases with advanced axillar tumor involvement or lymph
node capsule penetration the axillar region was added to
the target and treated to a dose of 46 to 50 Gy. Fractiona-
tion was conventional with 2 Gy daily. Six MeV photons
from an accelerator were used. The GTV was boosted to
the total dose of 60 to 64 Gy depending on the surgical
margin and using fast electrons from an accelerator. The
mean applied total dose was 60.1 Gy.
Patient and tumour characteristics
Hundred-nine consecutively treated patients with breast
cancer were prospectively analysed. Mean age was
55 years (26-81 years). Fourteen patients (12.9%) were
younger than 50 years, 58 (53.2%) were aged between
50 and 60 years, and 37 (33.9%) were older than 60 years.
All other tumour characteristics including stage distribu-
tion [17] are detailed in table 1. Pathology reports
revealed in 80.7% invasiv ductal and in 9.2% invasiv lobu-
lar carcinoma; in 3.7% a DCIS was found. Other entities
were summarized in the remaining cohort.
Performed surgical modality was in 86.2% a segmen-
tectomy, in 8.3% a lumpectomy, and in 3.7% a quadran-
tectomy. In two cases a mastectomy with expander
reconstruction was performed. Mean minimal resection
margin was 0.5 cm (range 0 to 2 cm). Axillary lymph
n o d ed i s s e c t i o nw a sp e r f o r m e di n9 7 . 2 % ,i n2 0 . 2 %b y
using the sentinel lymph node biopsy method. Mean
number of removed lymph nodes was 16.5 (0-29). In
Figure 1 Clinical assessment of breast anatomy and marking.
Figure 2 Target volume definition on CT.
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was not performed. Postoperative complications after
breast cancer surgery (e. g. mastitis, thrombophlebitis,
wound complications) were generally not severe and
occurred in 31.2% of the patients; 68.8% were complica-
tion-free. Seroma development was the most frequent
postoperative complication in 11.9%. Estrogen receptor
status was in 64.2% positive, mean score was 6 (range
1-12). In 35.8% estrogen receptor status was negative.
Progesterone receptor status was in 57.8% positive,
mean score was 4.9 (range 1-12). In 42.2% progesterone
receptor status was negative.
Adjuvant therapy, radiotherapy techniques
Adjuvant systemic treatment was carried out in patients
with one or more poor prognostic factors (high T-stage,
lymph node involvement, high grading, negative estro-
gen and/or progesterone receptor status), and initiated
following surgery. Forty-one patients were treated with
adjuvant chemotherapy: in 31 patients with CMF (cyclo-
phosphamide/methotrexate/5-FU)-chemotherapy and all
other patients with EC (epirubicin/cyclophosphamide).
Forty-five patients were treated by adjuvant hormonal
therapy with tamoxifen.
Seventy-one (65.1%) patients were irradiated with a
tangential 2-field-technique (breast only), and 38 (34.8%)
locoregionally with an asymmetric 3-field-technique
(24 supraclavicular region only, and 14 supraclavicular/
axillar region). The median total dose was 60 Gy (GTV).
T h em e d i a nd o s ei nt h eb r e a s tw a s5 0G y ,a n di nt h e
axilla and/or the supraclavicular region it was 46 Gy.
Assessment of therapy-related toxicity
Toxicity was measured using a newly developed topo-
graphic module. The instrument contained six sections:
skin, breast, axilla, arm, general symptoms, and impair-
ments by therapy. Those sections were subdivided in 15
scales: skin 2 scales, breast 3 scales, axilla 3 scales, arm
2 scales, other symptoms 1 scale, general symptoms 3
scales, and impairment by radiation 1 scale. All scales
were scored according to symptom intensity of CTC-
classification in maximal 5 severity grades from grade 0
(no events) to grade 5 (death related to adverse events).
The skin was evaluated in the scales “pigmentation” and
“dermatitis”. Breast was evaluated according “symmetry”,
“lymphedema”,a n d“pain”. Axillary toxicity was scored
in “pain”, “hair loss”, “sweat gland function”.F o rt h e
ipsilateral arm “lymphedema”,a n d“function/mobility”
were assessed. General symptoms (appetite, nausea, and
Karnofsky [18] index) were also rated. The scale
“impairments by radiotherapy” judged (actively
requested by the physician) overall difficulties from
patient’s perspective caused by therapy in 5 severity
grades as well. Data were analysed using the Statistical
Package for the Social Sciences (SPSS) for Windows.
Results
Mean grades of symptom severity were calculated for all
scales during the acute phase of radiotherapy (t1 to t8).
Toxicity was generally very low. The mean grade did
n o te x c e e dt h em a x i m u mo f1 . 0 5 7( w i t hap o s s i b l e
range from 0 to 5). Clinically relevant grade 3-toxicity
was extremely low and seen in three scales only: “skin
dermatitis”, “breast symmetry”,a n d“breast lymphe-
dema” (table 2). Severe toxicity ≥ grade 4 was not
observed. In all other scales only mild to moderate or
no events events (grade 0-2) were registered.
Longitudinal analyses
Skin toxicity was recorded according “dermatitis” and
“pigmentation”. Hyperpigmentation was first seen in the
third radiation week (mean grade 0.033) and climbed
slightly to sixth therapy week (mean grade 0.341). At t8
the mean grade dropped again to 0.20. Dermatitis mean
grade increased from the second to last radiation week
as well and decreased to t8 (0.229). It was most severe
at t6 (mean grade 0.912). Longitudinal skin toxicity var-
iations are detailed in figure 3. Generally, dermatitis was
more pronounced than hyperpigmentation.
Table 1 Tumor characteristics
Variable N Valid Percentage
T-Stage
according UICC
pT1 66 60.6
pT2 38 34.8
pT3 1 0.9
Tis 4 3.7
N-Stage
according UICC
pN0+cN0 68+3 65.1
pN1a 7 6.4
pN1bi 12 11.0
pN1bii 5 4.6
pN1biii 11 10.1
pN1biv 2 1.8
pN2 1 0.9
Grading
G1 6 5.5
G2 55 50.5
G3 34 31.2
Unknown 14 12.8
Total 109 100
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“lymphedema”,a n d“pain”.I nt h es c a l e“symmetry” a
relatively low toxicity level was observed at t1 (post-
operative status), which remained constant to t8 (0.944 -
1.057). The scales breast “lymphedema” and “pain”
showed the same pattern of longitudinal variations at
very low levels. Longitudinal breast toxicity variations
are displayed in figure 4. Axillar adverse events were
documented according “hair loss”, “sweat gland func-
tion”,a n d“pain”. Toxicity levels in the scales “hair loss”
and “sweat gland function” were clinically insignificant
(mean grades close to 0). Registered axillar pain was at
t1 (postoperative status) low (mean grade 0.57, garde 0
in 51,61%, grade 1 in 39,78%, and grade 2 in 8,60%,
grade ≥ grade 3 in 0%) and decreased longitudinally to
0.143 (mean grade at t8). Hair loss and sweat gland
function toxicitiy observations revealed very low to 0
levels of toxicity.
For the ipsilateral arm scales “lymphedema”, and “func-
tion/mobility” were assessed. Arm function was at initial
registration (postoperative status/radiotherapy begin)
only slightly reduced. However, arm function/mobility
Table 2 Toxicity documentation: measurement points t1-t8 (Percentages)
Scale Mesurement-point Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Skin: Dermatitis t1 91.01% 6.74% 1.12% 1.12% 0.00%
t2 86.96% 11.96% 1.09% 0.00% 0.00%
t3 75.00% 22.83% 2.17% 0.00% 0.00%
t4 58.06% 37.63% 3.23% 1.08% 0.00%
t5 33.70% 47.83% 17.39% 1.09% 0.00%
t6 28.57% 51.65% 19.78% 0.00% 0.00%
t8 80.00% 17.14% 2.86% 0.00% 0.00%
Skin: Pigmentation t1 100.00% 0.00% 0.00% 0.00% 0.00%
t2 100.00% 0.00% 0.00% 0.00% 0.00%
t3 96.74% 3.26% 0.00% 0.00% 0.00%
t4 95.70% 4.30% 0.00% 0.00% 0.00%
t5 89.13% 10.87% 0.00% 0.00% 0.00%
t6 67.03% 31.87% 1.10% 0.00% 0.00%
t8 80.00% 20.00% 0.00% 0.00% 0.00%
Breast: Symmetry t1 34.44% 40.00% 22.22% 3.33% 0.00%
t2 33.70% 40.22% 22.83% 3.26% 0.00%
t3 33.70% 40.22% 22.83% 3.26% 0.00%
t4 33.33% 40.86% 22.58% 3.23% 0.00%
t5 32.61% 41.30% 22.83% 3.26% 0.00%
t6 31.87% 42.86% 23.08% 2.20% 0.00%
t8 25.71% 45.71% 25.71% 2.87% 0.00%
Breast: Lymphedema t1 28.89% 66.67% 4.44% 0.00% 0.00%
t2 32.61% 64.13% 3.26% 0.00% 0.00%
t3 29.35% 66.30% 3.26% 1.09% 0.00%
t4 22.58% 73.12% 4.30% 0.00% 0.00%
t5 21.74% 73.91% 4.35% 0.00% 0.00%
t6 20.88% 74.73% 4.40% 0.00% 0.00%
t8 25.71% 71.43% 2.86% 0.00% 0.00%
Breast: Pain t1 84.44% 12.22% 3.33% 0.00% 0.00%
t2 84.78% 14.13% 1.09% 0.00% 0.00%
t3 84.78% 11.96% 3.26% 0.00% 0.00%
t4 83.87% 13.98% 2.15% 0.00% 0.00%
t5 76.09% 21.74% 2.17% 0.00% 0.00%
t6 79.12% 17.58% 3.30% 0.00% 0.00%
t8 91.43% 8.57% 0.00% 0.00% 0.00%
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Arm lymphedema played a minor role. This data accord-
ing axilla and ipsilateral arm toxicity is shown in table 3.
General symptoms (appetite, nausea, and Karnofsky
index) were also recorded and revealed only minor
impairments during the complete acute phase of radio-
therapy. “Impairments by radiotherapy” which were over-
all difficulties caused by therapy, showed minor stress
with a slight increase at the end of therapy (grade 1 in
3 7 . 4 % ,a n dg r a d e2i n1 . 1 % ) .H o w e v e r ,a tt 8( 3m o n t h s
after therapy initiation) only 2.86% of the patients experi-
enced a grade 1 toxicity level and no grade 2 was
registered.
Univariate analyses by age
Univariate analyses revealed slightly higher toxicity in
older (> 60 years) versus young patients (< 50 years) in
2 toxicity scales: breast-symmetry (p = 0.033), and arm
function (p = 0.007). However, in the scale “appetite”
registred toxicity was higher in younger (< 50 years) ver-
sus older (> 60 years) patients (p = 0.039). Toxicity dif-
ferences in all other scales were not significant. Between
older (> 60 years) and midaged patients (50-60 years) no
statistically significant differences in toxicity could be
detected. This was also true for the comparison between
young (< 50 years) versus midaged patient groups
(50-60 years).
Discussion
The present study addresses by using a prospective
design specifically the radiotherapy toxicity in 109
patients during the acute phase (day 0 to day 90 from
radiotherapy initiation) of postoperative breast 3D con-
formal irradiation following breast-conserving surgery.
Mean age in the analyzed study cohort was 55 years.
Toxicity assessment and documentation modeled accord-
ing to the international CTC classification for acute toxi-
city in oncology [10] using new developed instruments
[11,12]. Classical CTC criteria were supplemented by
radiotherapy specific aspects. Longitudinal analyses
showed, as expected, a slight increase in skin radiother-
apy reactions (pigmentation and dermatitis) during the
course of irradiation. However, the continuous decrease
of axillar pain and arm dysfunction registering the high-
est level of toxicity at therapy initiation was rather
surprising. Surprisingly was also that the postoperative
level of physical deficits at radiotherapy begin (t1) was
relatively low, and this level even decreased during post-
operative radiotherapy. Generally, the registered overall
mean grade of toxicity was very low: 0 to 1.057, which
supports the breast- conserving therapy as a treatment
entity consisting of surgery, irradiation, and systemic
treatment. Literature reports of acute toxicity for radio-
therapy after breast-conserving surgery are infrequent.
This endpoint is historically neglected, although acute
toxicity is discriminating against good or poor compli-
ance, and this is especially true by stratifying to the vari-
able “age”. Vicini et al. [19] reported 281 patients treated
with intensity modulated 3D radiotherapy. No patient
showed skin toxicity higher than grade 3. Grade 0 or 1
toxicity was registered in 157 (56%), grade 2 in 102
patients (43%), and grade 3 in only three women (1%).
This was in concordance to our results with only 1.1%
grade 3-dermatitis at measurement point t 5. Grade 1
and 2 skin reactions were registered in our study popula-
tion highest at the end of radiation (t 6) with 51.65% and
19.78%, respectively.
Gruber and coworkers could show that the expansion
of treated volume to the locoregional lymphnodes for
patients with extranodal tumor invasion and/or other
negative prognostic factors provides a sufficient com-
pensation for better survival [20]. In our study popula-
tion 22% of the patients were irradiated also in the
supraclavicular region, and 12.8% in both axillar and
supraclavicular areas. However, toxicity levels according
axilla and arm scales were extremely low. In fact, axillar
pain did improve from initial level of 39.8% grade 1 and
Figure 3 Temporal variations of scale means of skin toxicity by
measurement point (mean grade).
Figure 4 Temporal variations of scale means of breast toxicity
by measurement point (mean grade).
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and 0% grade 2 at measurement point t8. Arm function
showed the same favorable kinetics from 53.8% grade 1
and 6.4% grade 2 at measurement point t1 to 28.6%
grade 1 and 0% grade 2 at measurement point t8. These
findings support the assumption that the postoperative
healing process in the axilla and the ipsilateral arm is
not affected or significantly disturbed by moderate doses
of radiotherapy of 46 Gy. Arm lymphedema was, how-
ever, consistently observed at low levels throughout of
the entire study observation period of three months
with no improving or deteriorating temporal trend.
Toxicities grade 3 or higher were not observed in this
regard. Albrecht et al. [21] compared 129 patients with
axillar radiotherapy after breast-conserving surgery ver-
sus 173 patients after breast-conserving surgery and
axillar dissection. Arm lymphedema, axillar pain and
arm function restrictions were observed in 26% of
women with axilla surgery, but in only 1% following
axillar radiotherapy. These data confirm our results of
low toxicity following locoregional radiation therapy in
addition to breast-conserving surgery. At measurement
Table 3 Toxicity documentation: measurement points t1-t8 (Percentages)
Scale Mesurement-point Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Axilla: Pain t1 51.61% 39.78% 8.60% 0.00% 0.00%
t2 52.17% 40.22% 7.61% 0.00% 0.00%
t3 53.26% 41.30% 5.43% 0.00% 0.00%
t4 58.06% 38.71% 3.23% 0.00% 0.00%
t5 56.52% 42.39% 1.09% 0.00% 0.00%
t6 63.74% 35.16% 1.10% 0.00% 0.00%
t8 85.71% 14.29% 0.00% 0.00% 0.00%
Axilla: Hair loss t1 100.00% 0.00% 0.00% 0.00% xxx
t2 98.91% 1.09% 0.00% 0.00% xxx
t3 100.00% 0.00% 0.00% 0.00% xxx
t4 97.85% 1.08% 1.08% 0.00% xxx
t5 98.91% 1.09% 0.00% 0.00% xxx
t6 100.00% 0.00% 0.00% 0.00% xxx
t8 100.00% 0.00% 0.00% 0.00% xxx
Axilla: sweat gland function t1 100.00% 0.00% 0.00% 0.00% xxx
t2 100.00% 0.00% 0.00% 0.00% xxx
t3 100.00% 0.00% 0.00% 0.00% xxx
t4 100.00% 0.00% 0.00% 0.00% xxx
t5 100.00% 0.00% 0.00% 0.00% xxx
t6 100.00% 0.00% 0.00% 0.00% xxx
t8 100.00% 0.00% 0.00% 0.00% xxx
Arm: Lymphedema t1 62.37% 37.63% 0.00% 0.00% 0.00%
t2 60.87% 38.04% 1.09% 0.00% 0.00%
t3 63.04% 36.96% 0.00% 0.00% 0.00%
t4 61.29% 38.71% 0.00% 0.00% 0.00%
t5 61.96% 38.04% 0.00% 0.00% 0.00%
t6 62.64% 37.36% 0.00% 0.00% 0.00%
t8 60.00% 37.14% 2.86% 0.00% 0.00%
Arm: Function t1 39.78% 53.76% 6.45% 0.00% 0.00%
t2 42.39% 54.35% 3.26% 0.00% 0.00%
t3 46.15% 52.75% 1.10% 0.00% 0.00%
t4 48.39% 51.61% 0.00% 0.00% 0.00%
t5 53.26% 46.74% 0.00% 0.00% 0.00%
t6 59.34% 39.56% 1.10% 0.00% 0.00%
t8 71.43% 28.57% 0.00% 0.00% 0.00%
Galalae et al. Radiation Oncology 2010, 5:103
http://www.ro-journal.com/content/5/1/103
Page 7 of 9point t8 (6 weeks after radiotherapy) 97.1% of the pre-
sent study patients had no impairments from radiother-
a p ya ta l la n do n l y2 . 8 %s t a t e dv e r yl o wg e n e r a l
restrictions or burdens due to radiotherapy. Longitudin-
ally only 1.1% of the women complained at measure-
ment point t6 moderate stress (grade 2) in the course of
radiotherapy. Nagel and coworkers [22] confirmed in a
field study with breast cancer patients a high rate of
adjuvant radiotherapy in addition to breast-conserving
surgery of 90.6%. The study documented a very impress-
ive high level of acceptance of adjuvant radiotherapy
after breast-conserving surgical care which was in con-
cordance with our results. However, univariate analyses
in this trial revealed higher age and co-morbidity as
negative prognostic variables for use of radiotherapy.
This finding did not correspond to our study results.
We could not demonstrate a significant difference in
toxicity discriminating between the different age groups:
<50 years versus 50-60 versus >60 years. However, we
admit limitations in terms of cohort sample size, and
considering chronological age and not the biological age.
Conclusion
These prospective measurement results of toxicity
according CTC-classification during postoperative adju-
vant 3D radiotherapy following breast-conserving surgery
demonstrated very low side-effect levels throughout the
entire acute treatment phase. Thus, the BCT concept for
breast cancer was generally very well tolerated. On the
contrary, postoperative radiation did not impaired recov-
ery from surgery. Axillar pain and arm dysfunction
improved continuously during irradiation course. Toxi-
city-measurement with the new topographic module was
feasible. Univariate analyses by age could not reveal clini-
cal meaningful differences between the assessed young
and older study cohorts. In consequence, not modified
standard treatments for breast cancer should be per-
formed in elderly population as well. Further longitudinal
data is needed to assess temporal outcome variations at
long-term follow-up.
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